Amnion Life

Early Stage

Safer, fluid-filled incubator to keep premature infants healthy.


Raised to Date: Raised: $281,292

Total Commitments ($USD)



Start Date


Close Date


Min. Goal
Max. Goal
Min. Investment


Security Type


SEC Filing Type

RegCF    Open SEC Filing

Valuation Cap




Rolling Commitments ($USD)

Reporting Date


Days Remaining
% of Min. Goal
% of Max. Goal
Likelihood of Max
Avg. Daily Raise


# of Investors


Create a free account today to gain access to KingsCrowd analytics.
Year Founded



Healthcare & Pharmaceuticals

Tech Sector



Newport Beach, California

Nearly 15M infants worldwide are born premature. Due to underdeveloped organs, the dramatic shift from amniotic fluid to air puts them at risk for hypothermia, dehydration, and infections which can lead to sepsis, organ injuries, and even death. To substantially improve preterm infants' chances of survival and reduce the time needed in intensive care, we designed AmnioBed, a patented, cost-efficient, fluid-filled solution that mimics a mother's amniotic fluid.
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
Amnion Life 10/15/2020 Wefunder $7,500,000 $162,040 SAFE Funded RegCF
Amnion Life 10/07/2019 Self Managed - $0 Debt Funded RegD 506(c)
Amnion Life 04/16/2019 Wefunder $22,500,000 $281,292 SAFE Funded RegCF
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)


$12.42 /month
billed annually
Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings (excluding risk)
Advanced company search ( with ratings)
Markets page filters and historical industry data
Get Edge Annual

Edge Pro

$41.58 /month
billed annually
Full site access including KingsCrowd's qualitative analyst reports.
Plan Includes:
Everything in Edge, plus
Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
Search and filter based on Analyst Reports
In-depth risk ratings for every raise
Get Edge Pro Annual
Already a member? Log in here.

Analyst Report Analyst Report Methodology Article


As of January 24th, Amnion Life has raised $150.1K via Wefunder and $1M via 2 prior seed rounds.

Amnion Life has been selected as a “Top Deal” by KingsCrowd. This distinction is reserved for deals selected into the top 10% of our deal diligence funnel. Check out our discussion with Founder & CEO, Amir Fassihi HERE, which was conducted as part of our due diligence process.


Did you know that more than 50% of infants born before 25 weeks don’t survive, and that the leading cause of death among children under 5 years of age is premature birth? In 2015, there were 1M premature infants that died globally.

It is estimated by the World Health Organization that ¾’s of these deaths can be prevented with cost-effective care. For babies that survive and make it out of the NICU, their future prospects can also be grim, with most babies falling into the lowest 10th percentile of infants in terms of height and weight.

One such method that could help with this is ‘kangaroo mother care,’ (the baby is carried by the mother with skin-to-skin contact and frequent breastfeeding). Now the reality is, when infants are that premature, this type of care can be near impossible because the baby is just too fragile.

A solution is needed that provides premature infants with an environment that mimics that of a mother’s womb. A place that provides the type of moisture, static temperature and nutrition that a premature infant needs to develop like a full-term baby.

Unfortunately, current NICU solutions that try and provide the closest thing to ‘kangaroo mother care,’ are too hostile with heat lamps that dry the infant’s skin, and humidified portholes that need to be opened and shut for evaluations, which create too much variation in temperature for the infant to maintain homeostasis.


Amnion Life is a revolutionary effort to improve on the incubators we have now. Their iteration of the incubator, the AmnioBed, recreates the conditions inside the womb to minimize the amount that infants need to adapt to new external conditions.

The AmnioBed is designed with water that contains minerals, electrolytes, and other essential nutrients, and heats the solution to 98.6 F, the body temperature that the infant would normally be exposed to inside the womb. Infants are then submerged in this solution with a harness to ensure the infant’s head is above water at all times. Infants can, therefore, absorb nutrients through their skin from the AmnioBed’s water and maintain healthy body temperatures. It’s the closest thing to a mother’s womb that has ever been created.

There are a number of advantages to using the AmnioBed. First, water is much more efficient at transferring heat than air. The fact that the baby is submerged in heated water, rather than the current practice of portholes, means that an infant’s body temperature can be kept at a healthy level more consistently than with current devices.

Even more, when an infant needs to undergo assessments, the AmnioBed’s water also does not have to take 20 minutes to rebalance interior conditions. Because of AmnioBed’s water composition, infants are also able to absorb essential nutrients through their skin from the surrounding water, much like they would inside the womb, which is a significant improvement on the current practice of using IVs.

IV saline, which is used to replace water loss from their underdeveloped skin, has also been associated with chronic lung disease and is risky when not administered with the correct balance of other nutrients. In essence, there are many advantages to keeping premature infants in womb-like conditions that current practices cannot address.

With 15 million infants born premature globally every year, the market for for neonatal intensive care is valued at $6.2B, and is forecasted to grow to $9.09Bn by 2024. A new solution that is less abrasive than current incubator solutions that can lead to timelier release of premature infants and decreased mortality rate is desperately needed.

With neonatal intensive care unit (NICU) costing nearly $3,000 per day, any solution that can reduce time in the NICU and improve outcomes will be positively received by the medical community. Amnion Bed’s technology seems poised to provide a truly promising solution to drastically improve the current standard of care.

Product Roadmap

Amnion Life, founded in 2016, has simultaneously made headway in realizing the potential of their innovations and generating additional uses for their intellectual property rights.

In April of 2018, the first prototype of the AmnioBed was completed, and the company is in the process of testing their prototype.

Even more, they hope to design and develop a secondary device to mimic the umbilical cord, where incubators may provide essential nutrients and oxygen to an infant’s umbilical vessels, where they would naturally receive their nutrition. Further down the line, they also hope to create similar long-term care units for adult burn victims and other patients. This platform approach further enhances the long term prospects of this business.

Why We Like it

1. Strong Stakeholder Incentives: AmnioBed is based on the concept that given the right care, premature infants may have a higher growth rate, and therefore be discharged from hospitals sooner.

Currently, preterm infants stay in the NICU for 46 days on average. These numbers are even higher for extreme preterm infants, with Florida reporting a 110 day stay on average.

This means that extreme preterm infants undergo nearly 42-46 weeks of gestation, compared to the normal 40-week gestation period. Given that the AmnioBed can provide better care and therefore reduce the time an infant takes to be discharged, hospitals will be able to service more infants in a shorter amount of time, with fewer incubators.

In fact, stakeholders on every side of premature births benefit from this innovation. Parents of infants can rest easier knowing that their infants are being kept in conditions similar to what other infants who were born at their due dates would undergo. Infants are clearly better off without the added risks of unstable external conditions, and the potential dangers of water and heat loss.

Society in general also benefits off of shorter hospitalization periods. With such a high cost associated with NICUs, a reduction of just three days in preterm infant length of stay represents a potential $1.1 Bn decrease in societal cost.

This comprehensive set of benefits to all stakeholders means that the AmnioBed is likely to be well-received by the market.

2. Strong Product-line Potential

In pioneering this new perspective on premature infant care, Amnion Life has an advantage over competitors in generating other products that perform similar functions. For example, their idea for creating what is essentially an artificial umbilical cord has similar implications and societal benefits as their AmnioBed.

Additionally, the business model is attractive from the fact that the device is only one way to monetize the technology. It’s very much a razor-razor blade model, where once they sell the unit to a hospital they will drive continued revenues off of selling consumables (amniotic fluid cartridges, catheters and lines, filters, etc.)  and maintenance of the equipment. This makes the top line revenue opportunities attractive as each unit drives long term recurring revenues.

Their plan to eventually expand into developing devices tailored for burn victims or other long-term care patients also represents the potential applications of their innovative new idea. This means, the company will not simply stop growing if it saturates the premature infant care market, but instead Amnion Life can expand to other aspects of the healthcare industry as well. Put simply, platform technologies help to create more market opportunity.

3. Long Investment Horizon & Risks

Amnion Life estimates that the AmnioBed may take two years of testing or more, to ensure that the product is market-ready. But, even after the company is satisfied with the quality and safety of their product, the FDA still needs to approve their product, which takes on average another six months. So, investments in Amnion Life are likely to have a long time horizon and inherently hold more risk, due to the potential that the FDA does not approve their product.


Amnion Life is solving a major pain point in the current treatment paradigm for premature infants. The $25MM market cap is justified due to the multi-billion dollar exit opportunity available should this team succeed. They have made significant progress in the development of this tech and there is a clear and unmet need, which should help support continued movement through the FDA regulatory approval process.

Clearly, stakeholders on all sides of preterm birth need an improvement on the status quo, and Amnion Life’s product has a lot of potential in successfully mitigating the effects of such premature births, with an intuitive solution that is 10X better than anything currently on the market. With a strong management team, an excellent vision for a technology platform that is truly differentiated and a business model that has proven succesful in the past we think this is a Top Deal with significant upside.

Though the long time horizon and approval risks associated with an investment into Amnion Life may inhibit certain investors, if their tests produce positive results and is accepted into the market, the company has a long way to grow, and will certainly have a higher valuation than $25MM.

Founder Profile

Founder Profile: A Med-Tech Device That Emulates A Mother’s Womb

When babies are born premature there are several challenges associated with trying to manage their body temperature, skin moisture and overall well being. Typically, all of these needs are met within a mother’s womb, which is specifically designed to take care of a babies needs prior to the end of a pregnancy term.

Unfortunately, no incubator or bed that has been created for premature infants has yet to resemble a mother’s womb in an exacting way, which can lead to complications and even death. CEO, Amir Fassihi and his team at Amnion Bed want to ensure these complications and deaths never occur again by creating a med device that mimics a mother’s womb in almost every way.

Read Founder Interview

Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.

Create your first portfolio

Create your own startup investment portfolio on KingsCrowd.

Track all of your startup investments in one place using our state-of-the-art portfolio tracker tools. To begin, create your first portfolio below.

Add to portfolio
Amnion Life on Wefunder
Platform: Wefunder
Security Type: SAFE
Valuation: $22,500,000

Follow company

Follow Amnion Life on Wefunder

Buy Amnion Life's Deal Report

Warning: according to the close date for this deal, Amnion Life may no longer be accepting investments.

Amnion Life Deal Report

Get KingsCrowd’s comprehensive report on Amnion Life including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Amnion Life is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise
  • What one of our expert analysts thinks about this investment opportunity

Buy the Amnion Life deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge Pro